Semaglutide

INTRODUCTION: Psoriasis and obesity often occur together, with up to 50% of patients with psoriasis being classified as obese. This increases systemic inflammation, cardiovascular risk, and disease severity while reducing the efficacy of biologic tre…

IMPORTANCE: Patients with diabetes and a history of major adverse limb events (MALEs) are at an increased risk of cardiovascular and limb-related complications; however, effective glucose-lowering therapies for secondary prevention in this population…

AIMS: To examine the impact of FDA approval of semaglutide (Wegovy) for chronic weight management on the utilization gap between males and females in the United States. MATERIALS AND METHODS: The study utilized 2019-2024 MarketScan commercial claims…

INTRODUCTION: In patients with type 2 diabetes mellitus (T2DM), cardiovascular (CV) disease and chronic kidney disease (CKD) drive excess morbidity and mortality. Beyond glucose-lowering, incretin-based therapies may provide organ protection across t…

BACKGROUND AND AIMS: The burden of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis is rapidly rising globally. There are several therapeutic agents under clinical development for the treatment of cirrhosis due to MASH; however, thei…

BACKGROUND AND AIMS: Polycystic ovary syndrome (PCOS) and obesity increase the risk of infertility, preterm birth and birth of a hypertrophic neonate. Effective weight loss can improve this disorder. The aim of this study was to evaluate the effect o…

OBJECTIVE: We examined whether the addition of GLP-1RA to progestin therapy reduced the risk of hysterectomy in patients with endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC) in the U.S. managed with fertility-sparing managemen…

BACKGROUND: Insulinomas are rare, typically benign pancreatic neuroendocrine tumors that cause endogenous hyperinsulinemic hypoglycemia. While usually diagnosed in middle age, their presence in young adults may suggest hereditary syndromes, such as M…

BACKGROUND: The intersection of obesity and asthma represents a complex clinical challenge characterized by increased symptom burden, reduced treatment efficacy, and multifactorial pathophysiology. Obesity-associated asthma is a heterogeneous conditi…

AIM: We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). METHODS: Patients with MASLD and…

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly prescribed for type 2 diabetes and obesity, have demonstrated potential anti-inflammatory and immunomodulatory effects that may be beneficial in chronic inflammatory skin conditions such…

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for the management of obesity and type 2 diabetes, particularly among women of reproductive age. Emerging evidence suggests potential effects on ovulation, fertility, and preg…

Consumers precluded from obtaining semaglutide or tirzepatide by clinicians or insurers are turning to natural "GLP-1" transdermal patches. The Dietary Supplement Health and Education Act specifies dietary supplement products must be swallowed, so al…

to assess the safety profile of Gastrointestinal (GIT), renal, and pancreatic effects of GLP-1 and dual receptor agonists.Disproportionality analyses were performed on FDA Adverse Event Reporting System (FAERS) data following each drug's approval for…

Targeted screening for steatotic liver disease (SLD) is cost-effective and encourages lifestyle changes.The European Association for the Study of the Liver (EASL) recommends screening adults at risk of SLD to enable timely diagnosis and prevention, e…

OBJECTIVE: This study aimed to assess weight and safety outcomes in a large national cohort of patients with overweight and obesity treated with GLP-1 medications via telehealth. METHODS: Data were obtained from deidentified EHRs for a random sample…